Rocket One Inc

Rocket One Inc(RKTO)股票分析

$0.407

+0.005 (+1.12%)收盤時

Loading chart…
最高
0.425
開盤
0.402
成交量加權均價
0.41
成交量
122.17K
市值
—
最低
0.391
成交金額
49.79K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Rocket One Inc. is an artificial intelligence (AI) semiconductor infrastructure company. The Company is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. It operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. It is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells.

AI 分析 of Rocket One Inc (RKTO)

賣出

Rocket One Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $0.41, which is down 70.11% year-to-date. The RSI is at an extremely low 17.995, indicating oversold conditions but also potential further declines. The company has reported negative net income for multiple quarters, with a recent loss of $3,832,651 in Q2 2026, and a forward P/E ratio of 0 suggests that earnings are not expected to improve in the near term. The main risk is the ongoing negative sentiment in the market, as evidenced by a 5-day change of -16.48% and a 20-day change of -37.39%.

估值指標

Rocket One Inc(RKTO)目前預期本益比為 0.00,5 年平均預期本益比為 。

預期本益比

5 年均值 P/E
目前P/E
0.00

預期 EV/EBITDA

5 年均值 EV/EBITDA
目前EV/EBITDA
0.00

預期股價營收比

5 年均值 P/S
目前P/S
0.00

事件時間軸

2026-11-03 (ET)

08:30:00

Hoth Therapeutics Ends Phase 2a Trial of HT-001 Early

2026-10-13 (ET)

16:30:00

Rocket One Signs Research Agreement with Virginia Commonwealth University

2026-10-06 (ET)

08:30:00

Rocket One Signs Patent License Agreement with Air Force

2026-09-22 (ET)

08:30:00

Rocket One Acquires 100% Membership Interests of Tracer Drone Technologies

2026-08-11 (ET)

08:30:00

Rocket One Joins Seagate Partner Program

資訊

RKTO 常見問題 —— 由 Alphio AI 解答

Rocket One Inc. is an artificial intelligence (AI) semiconductor infrastructure company. The Company is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. It operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. It is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells. It operates in the Healthcare sector.

Rocket One Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $0.41, which is down 70.11% year-to-date. The RSI is at an extremely low 17.995, indicating oversold conditions but also potential further declines. The company has reported negative net income for multiple quarters, with a recent loss of $3,832,651 in Q2 2026, and a forward P/E ratio of 0 suggests that earnings are not expected to improve in the near term. The main risk is the ongoing negative sentiment in the market, as evidenced by a 5-day change of -16.48% and a 20-day change of -37.39%.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易